Entresto US Sales Barriers Set To Be Removed By Strong Guidance

Sales prospects for Novartis AG's struggling Entresto have been boosted – especially in the US – by new global cardiology guidelines issued by three organizations containing stronger than expected recommendations for its use in treating heart failure.